bioRxivCancer Biology
A quantitative chemotherapy genetic interaction map reveals new factors associated with PARP inhibitor resistance
H.-M. Hu, X. Zhao, S. Kaushik, L. Robillard, A. Barthelet, K. K. Lin, A. Simmons, M. Raponi, T. C. Harding, S. Bandyopadhyay
Abstract
Nearly every cancer patient is treated with chemotherapy yet our understanding of factors that dictate response and resistance to such agents remains limited. We report the generation of a quantitative chemical-genetic interaction map in human mammary epithelial cells that charts the impact of knockdown of 625 cancer and DNA repair related genes on sensitivity to 29 drugs, covering all classes of cancer chemotherapeutics. This quantitative map is predictive of interactions maintained in cancer cell lines and can be used to identify new cancer-associated DNA repair factors, predict cancer cell line responses to therapy and prioritize drug combinations. We identify that GPBP1 loss in breast and ovarian cancer confers resistance to cisplatin and PARP inhibitors through the regulation of genes involved in homologous recombination. This map may help navigate patient genomic data and optimize chemotherapeutic regimens by delineating factors involved in the response to specific types of DNA damage.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
S. J. Pettitt, D. B. Krastev, … C. J. Lord·bioRxiv·Oct 14, 2017
- 5hmC enhances PARP trapping and restores PARP inhibitor sensitivity in chemoresistant BRCA1/2-deficient cells
Suhas S. Kharat, Arun Prakash Mishra, … Shyam K. Sharan·Journal of Biological ChemistryPeer-reviewed·Jun 19, 2025
- Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibition
K. Jamal, A. Galbiati, … J. V. Forment·bioRxiv·Jul 29, 2022
- Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells
K. E. Clements, T. Thakar, … G.-L. Moldovan·bioRxiv·Apr 3, 2018
- Mapping the Genetic Interaction Network of PARP inhibitor Response
Danny Simpson, Ling Jia, … Britt Adamson·bioRxiv·Aug 19, 2023
- Machine learning-based prediction of response to PARP inhibition across cancer types.
Katherine E. Hill, Ahmed Rattani, … Dimitrios Spentzos·medRxiv·Sep 27, 2019